GLP-1 & Weight-Loss Drug Market Statistics 2026
Forty-plus business and market statistics on the GLP-1 and weight-loss drug economy — market size, company revenue, adoption, cost, and FDA milestones — each figure sourced and linked.
How It Works
Obesity is the most prevalent chronic condition in the U.S. adult population, creating a vast eligible patient pool and permanent, mainstream demand for effective weight-management drugs.
Novo Nordisk (Ozempic, Wegovy) and Eli Lilly (Mounjaro, Zepbound) dominate the branded GLP-1 market, pouring billions into manufacturing capacity to meet demand.
New FDA indications — cardiovascular risk, obstructive sleep apnea — keep widening the addressable market and the insurance-coverage case beyond the original diabetes and weight-loss labels.
What the Data Shows
On this page
- How big is the GLP-1 and weight-loss drug market?
- How fast is the obesity-drug market expected to grow?
- How much money do Novo Nordisk and Eli Lilly make from these drugs?
- How many Americans take GLP-1 drugs?
- How much do GLP-1 drugs cost, and who pays?
- How common is obesity in the United States?
- When were the major GLP-1 and weight-loss drugs FDA-approved?
How big is the GLP-1 and weight-loss drug market?
The global GLP-1 receptor agonist market is large and expanding fast, with independent forecasts placing it between roughly $67 billion and $157 billion by the early 2030s depending on the segment and methodology.
- $156.71 billion — projected global GLP-1 receptor agonist market size by 2030 (CAGR 17.46%, 2025–2030).Source: Grand View Research
- $13.84B → $48.84B — global GLP-1 weight-loss drugs sub-segment, from 2024 to a projected 2030 (CAGR 18.54%, 2025–2030).Source: Grand View Research
- $6.62B → $77.24B — global anti-obesity medication market, from 2023 to a projected 2030 (CAGR 31.66%, 2024–2030).Source: Grand View Research
- $7.48B → $67.16B — global anti-obesity drugs market, from 2025 to a projected 2034 (CAGR 29.20%, 2026–2034).Source: Fortune Business Insights
- ~$130.6 billion — projected U.S. GLP-1 receptor agonist market revenue by 2033 (CAGR 12%, 2026–2033).Source: Grand View Research
How fast is the obesity-drug market expected to grow?
Wall Street analysts expect the obesity-drug market to multiply many times over by 2030, driven by rising demand and expanding insurance coverage.
- ~$100 billion by 2030 — Goldman Sachs Research projection for the global anti-obesity medications market, up more than 16x from ~$6 billion in 2023.Source: Goldman Sachs Research (2023)
- ~$105 billion by 2030 — Morgan Stanley Research projection for the global obesity drugs market (up from an earlier $77B forecast, and as high as $144 billion).Source: Morgan Stanley Research (2024)
- ~15 million U.S. adults — projected to be treated with anti-obesity medications by 2030 — roughly 13% penetration of the eligible U.S. population.Source: Goldman Sachs Research
How much money do Novo Nordisk and Eli Lilly make from these drugs?
Two companies dominate the branded market: Eli Lilly (Mounjaro, Zepbound) and Novo Nordisk (Ozempic, Wegovy), and their GLP-1 franchises now generate tens of billions of dollars a year.
- $22.97 billion (+99%) — Eli Lilly Mounjaro (tirzepatide) worldwide revenue, full-year 2025.Source: Eli Lilly FY2025 results
- $13.54 billion (+175%) — Eli Lilly Zepbound (tirzepatide) revenue, full-year 2025.Source: Eli Lilly FY2025 results
- $65.18 billion (+45%) — Eli Lilly total company revenue, full-year 2025, led by its incretin franchise.Source: Eli Lilly FY2025 results
- DKK 127.09 billion (+6%) — Novo Nordisk Ozempic (semaglutide) sales, full-year 2025.Source: Novo Nordisk FY2025 report
- DKK 79.11 billion (+36%) — Novo Nordisk Wegovy (semaglutide) sales, full-year 2025.Source: Novo Nordisk FY2025 report
- DKK 82.35 billion (+26%) — Novo Nordisk total Obesity care sales, full-year 2025.Source: Novo Nordisk FY2025 report
- DKK 309.06 billion — Novo Nordisk total net sales, full-year 2025 (+6% in DKK).Source: Novo Nordisk FY2025 report
- 45.6 million people — living with obesity and diabetes reached by Novo Nordisk in 2025.Source: Novo Nordisk Annual Report 2025
- $4.1 billion — Novo Nordisk U.S. manufacturing investment announced in 2024 (second fill & finish facility, Clayton, NC).Source: Novo Nordisk (2024)
How many Americans take GLP-1 drugs?
GLP-1 use has moved from niche to mainstream: about one in eight U.S. adults is currently taking one, and awareness is now near-universal.
- 18% — of U.S. adults say they have ever taken a GLP-1 drug (late 2025), up from 12% in 2024.Source: KFF Health Tracking Poll (2025)
- 12% — of U.S. adults say they are currently taking a GLP-1 drug (late 2025) — double the 6% recorded in 2024.Source: KFF Health Tracking Poll (2025)
- 38% — of adults who have taken GLP-1s report using them only to lose weight (2024).Source: KFF Health Tracking Poll (May 2024)
- 32% — of adults say they have heard “a lot” about GLP-1 drugs (2024) — a measure of mainstream awareness.Source: KFF Health Tracking Poll (May 2024)
How much do GLP-1 drugs cost, and who pays?
The drugs are expensive and straining public budgets: a majority of users struggle to afford them, and government spending on GLP-1s has surged several-fold since 2019.
- 56% — of GLP-1 users say it was difficult to afford the drugs — including 55% of those with insurance (late 2025).Source: KFF Health Tracking Poll (2025)
- 27% — of insured GLP-1 users say they paid the full cost of the drugs themselves (late 2025).Source: KFF Health Tracking Poll (2025)
- $27.5 billion — gross Medicare Part D spending on GLP-1s in 2024 — a five-fold increase since 2019 (before rebates).Source: KFF Medicare analysis (2024)
- 47% — of gross Medicare GLP-1 spending in 2024 went to Ozempic alone; semaglutide products were more than half.Source: KFF Medicare analysis (2024)
- ~$9 billion — gross Medicaid spending on GLP-1s in 2024 — a nine-fold increase from about $1 billion in 2019.Source: KFF Medicaid analysis (2024)
- 8%+ — of all Medicaid prescription-drug spending (before rebates) went to GLP-1s in 2024, up from 1% in 2019.Source: KFF Medicaid analysis (2024)
How common is obesity in the United States?
Obesity affects roughly four in ten U.S. adults, the public-health backdrop that underpins demand for weight-loss drugs.
- 40.3% — of U.S. adults had obesity during August 2021–August 2023 (NHANES, measured).Source: CDC / NCHS Data Brief 508
- 9.4% — of U.S. adults had severe obesity during August 2021–August 2023 (NHANES, measured).Source: CDC / NCHS Data Brief 508
- 39.2% vs 41.3% — adult obesity prevalence in men versus women (2021–2023); no significant overall difference.Source: CDC / NCHS Data Brief 508
- 2 states at 40%+ — Mississippi and West Virginia had adult obesity prevalence of 40% or higher in 2024 (self-reported, BRFSS).Source: CDC Adult Obesity Prevalence Maps (2024)
When were the major GLP-1 and weight-loss drugs FDA-approved?
The modern weight-loss drug market was built over a decade of FDA approvals, accelerating sharply after 2021.
- Dec 23, 2014 — FDA approves Saxenda (liraglutide) for chronic weight management.Source: FDA approval letter (NDA 206321)
- Dec 5, 2017 — FDA approves Ozempic (semaglutide) for type 2 diabetes.Source: FDA approval letter (NDA 209637)
- Jun 4, 2021 — FDA approves Wegovy (semaglutide) for chronic weight management.Source: FDA approval letter (NDA 215256)
- May 13, 2022 — FDA approves Mounjaro (tirzepatide) for type 2 diabetes.Source: FDA Drug Trials Snapshots
- Nov 8, 2023 — FDA approves Zepbound (tirzepatide) for chronic weight management.Source: FDA press announcement
- Mar 8, 2024 — FDA approves a Wegovy cardiovascular-risk-reduction indication — the first for a weight-loss drug.Source: FDA press announcement
- Dec 20, 2024 — FDA approves Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity.Source: FDA press announcement
How these statistics were sourced
Every figure on this page is traced to a primary or named source and linked inline: company financial reports (Novo Nordisk, Eli Lilly), U.S. government data (FDA approval records, CDC/NCHS), survey and spending analyses (KFF), and market-size projections from named research firms (Grand View Research, Fortune Business Insights) and investment banks (Goldman Sachs, Morgan Stanley). No number is estimated or invented by HighPeptides.
Read the caveats: market-size forecasts vary widely by firm and methodology; government spending figures are gross (before confidential rebates); CDC NHANES (measured) and BRFSS (self-reported) data are not directly comparable; and company revenue blends diabetes and obesity uses of the same molecule. Company figures reflect full-year 2025 results. Last reviewed September 2026.
Key Takeaways
- The global GLP-1 receptor agonist market is projected to reach $156.71 billion by 2030 (Grand View Research).
- Goldman Sachs Research projects the anti-obesity drug market could reach ~$100 billion by 2030, up from ~$6 billion in 2023.
- Eli Lilly Zepbound posted $13.54 billion in full-year 2025 revenue — up 175% year over year.
- Eli Lilly Mounjaro posted $22.97 billion in 2025 revenue (+99%).
- Novo Nordisk Wegovy sales reached DKK 79.11 billion in 2025 (+36%); Ozempic reached DKK 127.09 billion.
- 18% of U.S. adults say they have ever taken a GLP-1 drug (KFF, 2025).
- 12% of U.S. adults are currently taking a GLP-1 drug (KFF, 2025) — double the 6% in 2024.
- 40.3% of U.S. adults had obesity in 2021–2023 (CDC/NHANES).
- Gross Medicare Part D spending on GLP-1s hit $27.5 billion in 2024 — a five-fold jump since 2019 (KFF).
- 56% of GLP-1 users say the drugs are difficult to afford (KFF, 2025).
- Goldman Sachs estimates ~15 million U.S. adults may be on anti-obesity medications by 2030 (~13% of eligible adults).
- Wegovy (FDA-approved 2021) and Zepbound (2023) are the weight-management anchors driving the market.
- Market-size forecasts vary widely by firm and methodology ($67B–$157B across overlapping 2030–2034 windows) — treat any one projection as an estimate, not consensus.
- Gross Medicare and Medicaid spending figures do not reflect confidential manufacturer rebates, which lower the net cost.
- CDC obesity prevalence (NHANES, measured) and the state-level maps (BRFSS, self-reported) use different methods and are not directly comparable.
- Survey-based adoption rates (KFF) are self-reported and can differ from pharmacy dispensing data.
- Company revenue blends diabetes and obesity uses of the same molecule (e.g., semaglutide), so pure "weight-loss" revenue is not cleanly separable.
Frequently Asked Questions
How big is the GLP-1 drug market in 2026?
Independent forecasts place the global GLP-1 receptor agonist market in the $150+ billion range by 2030, with Grand View Research projecting $156.71 billion (17.46% CAGR, 2025–2030). Estimates vary by firm and by how the segment is defined.
Which companies sell the most GLP-1 and weight-loss drugs?
Eli Lilly and Novo Nordisk dominate. In full-year 2025, Lilly reported $22.97 billion for Mounjaro and $13.54 billion for Zepbound, while Novo Nordisk reported DKK 127.09 billion for Ozempic and DKK 79.11 billion for Wegovy.
How many Americans take GLP-1 drugs?
About 12% of U.S. adults are currently taking a GLP-1 drug and 18% say they have ever taken one, according to KFF’s late-2025 Health Tracking Poll — roughly double the 2024 figures.
Why are GLP-1 drugs so expensive?
They are high-demand branded drugs: 56% of users report difficulty affording them, and gross Medicare Part D spending on GLP-1s reached $27.5 billion in 2024, a five-fold rise since 2019.
When did the FDA approve Wegovy and Zepbound?
The FDA approved Wegovy for chronic weight management on June 4, 2021, and Zepbound on November 8, 2023. Wegovy later gained a cardiovascular-risk-reduction indication on March 8, 2024.
🛒 Recommended Products
Support supplements and gear relevant to this protocol.
Affiliate links — support HighPeptides at no extra cost.
📚 Related HighPeptides Research
This page aggregates business, market, and public-health statistics for educational purposes only. It is not medical advice and makes no claim about the safety or efficacy of any drug. Always consult a qualified healthcare provider.
Figures are sourced from the cited publishers as of their stated dates. Market forecasts are third-party estimates that vary by methodology.